Company
Burzynski Research Institute, Inc.
Headquarters: Houston, TX, United States
CEO: Dr. Stanislaw R. Burzynski
Market Cap
$5.8 Million
USD as of Jan. 1, 2024
Burzynski Research Institute, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Burzynski Research Institute, Inc. operates a research and development facility of drugs for use in the treatment of cancer in the United States. The company engages in the research, development, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons name. It also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Burzynski Research Institute, Inc. has the following listings and related stock indices.
Stock: OTC: BZYR wb_incandescent